nodes	percent_of_prediction	percent_of_DWPC	metapath
Praziquantel—CYP3A4—bone cancer	0.877	1	CbGaD
Praziquantel—Palonosetron—CYP3A4—bone cancer	0.00879	1	CrCbGaD
Praziquantel—CYP3A43—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00734	0.1	CbGpPWpGaD
Praziquantel—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00392	0.0536	CbGpPWpGaD
Praziquantel—CYP3A43—Xenobiotics—CYP3A4—bone cancer	0.00354	0.0484	CbGpPWpGaD
Praziquantel—CYP3A43—Metapathway biotransformation—CYP4V2—bone cancer	0.00316	0.0432	CbGpPWpGaD
Praziquantel—CYP3A7—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00296	0.0404	CbGpPWpGaD
Praziquantel—Diarrhoea haemorrhagic—Epirubicin—bone cancer	0.00238	0.058	CcSEcCtD
Praziquantel—Diarrhoea haemorrhagic—Doxorubicin—bone cancer	0.0022	0.0537	CcSEcCtD
Praziquantel—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00214	0.0292	CbGpPWpGaD
Praziquantel—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00165	0.0226	CbGpPWpGaD
Praziquantel—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00153	0.0209	CbGpPWpGaD
Praziquantel—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00152	0.0208	CbGpPWpGaD
Praziquantel—CYP3A43—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00147	0.0201	CbGpPWpGaD
Praziquantel—CYP3A43—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00145	0.0198	CbGpPWpGaD
Praziquantel—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.00144	0.0197	CbGpPWpGaD
Praziquantel—CYP3A7—Xenobiotics—CYP3A4—bone cancer	0.00143	0.0195	CbGpPWpGaD
Praziquantel—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.00137	0.0187	CbGpPWpGaD
Praziquantel—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00129	0.0176	CbGpPWpGaD
Praziquantel—CYP3A7—Metapathway biotransformation—CYP4V2—bone cancer	0.00127	0.0174	CbGpPWpGaD
Praziquantel—CYP3A43—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00119	0.0163	CbGpPWpGaD
Praziquantel—Body temperature increased—Carboplatin—bone cancer	0.00113	0.0274	CcSEcCtD
Praziquantel—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.00107	0.0147	CbGpPWpGaD
Praziquantel—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.00103	0.0141	CbGpPWpGaD
Praziquantel—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000993	0.0136	CbGpPWpGaD
Praziquantel—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000991	0.0136	CbGpPWpGaD
Praziquantel—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000934	0.0128	CbGpPWpGaD
Praziquantel—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000919	0.0126	CbGpPWpGaD
Praziquantel—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000876	0.012	CbGpPWpGaD
Praziquantel—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000797	0.0109	CbGpPWpGaD
Praziquantel—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000767	0.0105	CbGpPWpGaD
Praziquantel—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000742	0.0101	CbGpPWpGaD
Praziquantel—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000733	0.01	CbGpPWpGaD
Praziquantel—Bone disorder—Methotrexate—bone cancer	0.000712	0.0173	CcSEcCtD
Praziquantel—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000711	0.00972	CbGpPWpGaD
Praziquantel—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000708	0.00968	CbGpPWpGaD
Praziquantel—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000705	0.00964	CbGpPWpGaD
Praziquantel—Abdominal discomfort—Cisplatin—bone cancer	0.000705	0.0172	CcSEcCtD
Praziquantel—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000695	0.0095	CbGpPWpGaD
Praziquantel—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000676	0.00924	CbGpPWpGaD
Praziquantel—Bone disorder—Epirubicin—bone cancer	0.000666	0.0162	CcSEcCtD
Praziquantel—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000654	0.00894	CbGpPWpGaD
Praziquantel—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000647	0.00884	CbGpPWpGaD
Praziquantel—CYP3A43—Biological oxidations—CYP3A4—bone cancer	0.000633	0.00865	CbGpPWpGaD
Praziquantel—CYP3A43—Metapathway biotransformation—CYP3A4—bone cancer	0.000624	0.00854	CbGpPWpGaD
Praziquantel—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000621	0.00849	CbGpPWpGaD
Praziquantel—Atrioventricular block—Epirubicin—bone cancer	0.00062	0.0151	CcSEcCtD
Praziquantel—Bone disorder—Doxorubicin—bone cancer	0.000616	0.015	CcSEcCtD
Praziquantel—Bradycardia—Cisplatin—bone cancer	0.000599	0.0146	CcSEcCtD
Praziquantel—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000597	0.00816	CbGpPWpGaD
Praziquantel—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000592	0.00809	CbGpPWpGaD
Praziquantel—CYP3A7—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000584	0.00799	CbGpPWpGaD
Praziquantel—Atrioventricular block—Doxorubicin—bone cancer	0.000574	0.014	CcSEcCtD
Praziquantel—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000554	0.00757	CbGpPWpGaD
Praziquantel—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000547	0.00748	CbGpPWpGaD
Praziquantel—Cardiac disorder—Cisplatin—bone cancer	0.000546	0.0133	CcSEcCtD
Praziquantel—CYP3A43—Biological oxidations—GSTP1—bone cancer	0.000542	0.0074	CbGpPWpGaD
Praziquantel—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000537	0.00733	CbGpPWpGaD
Praziquantel—CYP3A43—Metapathway biotransformation—GSTP1—bone cancer	0.000534	0.0073	CbGpPWpGaD
Praziquantel—Immune system disorder—Cisplatin—bone cancer	0.000531	0.0129	CcSEcCtD
Praziquantel—Arrhythmia—Cisplatin—bone cancer	0.000526	0.0128	CcSEcCtD
Praziquantel—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00048	0.00656	CbGpPWpGaD
Praziquantel—Ill-defined disorder—Cisplatin—bone cancer	0.000475	0.0116	CcSEcCtD
Praziquantel—Malaise—Cisplatin—bone cancer	0.000462	0.0112	CcSEcCtD
Praziquantel—Convulsion—Cisplatin—bone cancer	0.000444	0.0108	CcSEcCtD
Praziquantel—Myalgia—Cisplatin—bone cancer	0.000436	0.0106	CcSEcCtD
Praziquantel—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000433	0.0105	CcSEcCtD
Praziquantel—Discomfort—Cisplatin—bone cancer	0.000431	0.0105	CcSEcCtD
Praziquantel—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000428	0.00585	CbGpPWpGaD
Praziquantel—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000427	0.00584	CbGpPWpGaD
Praziquantel—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000422	0.00577	CbGpPWpGaD
Praziquantel—Nervous system disorder—Cisplatin—bone cancer	0.00041	0.00998	CcSEcCtD
Praziquantel—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000406	0.00555	CbGpPWpGaD
Praziquantel—Skin disorder—Cisplatin—bone cancer	0.000406	0.00989	CcSEcCtD
Praziquantel—Eosinophilia—Methotrexate—bone cancer	0.000399	0.00973	CcSEcCtD
Praziquantel—Anorexia—Cisplatin—bone cancer	0.000398	0.0097	CcSEcCtD
Praziquantel—Abdominal discomfort—Methotrexate—bone cancer	0.000387	0.00942	CcSEcCtD
Praziquantel—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000381	0.00928	CcSEcCtD
Praziquantel—CYP3A43—Metabolism—NDUFA12—bone cancer	0.00038	0.00519	CbGpPWpGaD
Praziquantel—Eosinophilia—Epirubicin—bone cancer	0.000374	0.0091	CcSEcCtD
Praziquantel—Decreased appetite—Cisplatin—bone cancer	0.000363	0.00885	CcSEcCtD
Praziquantel—Gastrointestinal disorder—Cisplatin—bone cancer	0.000361	0.00879	CcSEcCtD
Praziquantel—Drowsiness—Methotrexate—bone cancer	0.00036	0.00876	CcSEcCtD
Praziquantel—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.00035	0.00479	CbGpPWpGaD
Praziquantel—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000347	0.00474	CbGpPWpGaD
Praziquantel—Eosinophilia—Doxorubicin—bone cancer	0.000346	0.00842	CcSEcCtD
Praziquantel—Feeling abnormal—Cisplatin—bone cancer	0.000344	0.00839	CcSEcCtD
Praziquantel—Drowsiness—Epirubicin—bone cancer	0.000337	0.0082	CcSEcCtD
Praziquantel—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000331	0.00452	CbGpPWpGaD
Praziquantel—Body temperature increased—Cisplatin—bone cancer	0.00033	0.00805	CcSEcCtD
Praziquantel—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000327	0.00446	CbGpPWpGaD
Praziquantel—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000319	0.00436	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—NT5C3A—bone cancer	0.000314	0.0043	CbGpPWpGaD
Praziquantel—Drowsiness—Doxorubicin—bone cancer	0.000311	0.00759	CcSEcCtD
Praziquantel—Hypersensitivity—Cisplatin—bone cancer	0.000308	0.0075	CcSEcCtD
Praziquantel—Bradycardia—Epirubicin—bone cancer	0.000308	0.00749	CcSEcCtD
Praziquantel—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000304	0.00416	CbGpPWpGaD
Praziquantel—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.0003	0.00411	CbGpPWpGaD
Praziquantel—Asthenia—Cisplatin—bone cancer	0.0003	0.0073	CcSEcCtD
Praziquantel—Cardiac disorder—Methotrexate—bone cancer	0.0003	0.0073	CcSEcCtD
Praziquantel—Immune system disorder—Methotrexate—bone cancer	0.000292	0.0071	CcSEcCtD
Praziquantel—Diarrhoea—Cisplatin—bone cancer	0.000286	0.00697	CcSEcCtD
Praziquantel—Bradycardia—Doxorubicin—bone cancer	0.000285	0.00693	CcSEcCtD
Praziquantel—Cardiac disorder—Epirubicin—bone cancer	0.00028	0.00683	CcSEcCtD
Praziquantel—Immune system disorder—Epirubicin—bone cancer	0.000273	0.00665	CcSEcCtD
Praziquantel—Arrhythmia—Epirubicin—bone cancer	0.00027	0.00657	CcSEcCtD
Praziquantel—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000268	0.00367	CbGpPWpGaD
Praziquantel—Vomiting—Cisplatin—bone cancer	0.000266	0.00647	CcSEcCtD
Praziquantel—Rash—Cisplatin—bone cancer	0.000264	0.00642	CcSEcCtD
Praziquantel—Dermatitis—Cisplatin—bone cancer	0.000263	0.00641	CcSEcCtD
Praziquantel—Ill-defined disorder—Methotrexate—bone cancer	0.000261	0.00635	CcSEcCtD
Praziquantel—Cardiac disorder—Doxorubicin—bone cancer	0.000259	0.00632	CcSEcCtD
Praziquantel—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000258	0.00352	CbGpPWpGaD
Praziquantel—CYP3A7—Biological oxidations—CYP3A4—bone cancer	0.000255	0.00349	CbGpPWpGaD
Praziquantel—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000254	0.00348	CbGpPWpGaD
Praziquantel—Malaise—Methotrexate—bone cancer	0.000253	0.00617	CcSEcCtD
Praziquantel—Immune system disorder—Doxorubicin—bone cancer	0.000253	0.00615	CcSEcCtD
Praziquantel—Vertigo—Methotrexate—bone cancer	0.000253	0.00615	CcSEcCtD
Praziquantel—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	0.000252	0.00344	CbGpPWpGaD
Praziquantel—Arrhythmia—Doxorubicin—bone cancer	0.00025	0.00608	CcSEcCtD
Praziquantel—Nausea—Cisplatin—bone cancer	0.000248	0.00605	CcSEcCtD
Praziquantel—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000247	0.00337	CbGpPWpGaD
Praziquantel—Ill-defined disorder—Epirubicin—bone cancer	0.000244	0.00594	CcSEcCtD
Praziquantel—Convulsion—Methotrexate—bone cancer	0.000244	0.00593	CcSEcCtD
Praziquantel—Myalgia—Methotrexate—bone cancer	0.000239	0.00583	CcSEcCtD
Praziquantel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000238	0.00579	CcSEcCtD
Praziquantel—Malaise—Epirubicin—bone cancer	0.000237	0.00578	CcSEcCtD
Praziquantel—Discomfort—Methotrexate—bone cancer	0.000236	0.00576	CcSEcCtD
Praziquantel—Vertigo—Epirubicin—bone cancer	0.000236	0.00576	CcSEcCtD
Praziquantel—Convulsion—Epirubicin—bone cancer	0.000228	0.00555	CcSEcCtD
Praziquantel—Ill-defined disorder—Doxorubicin—bone cancer	0.000226	0.0055	CcSEcCtD
Praziquantel—Nervous system disorder—Methotrexate—bone cancer	0.000225	0.00548	CcSEcCtD
Praziquantel—Myalgia—Epirubicin—bone cancer	0.000224	0.00545	CcSEcCtD
Praziquantel—Skin disorder—Methotrexate—bone cancer	0.000223	0.00543	CcSEcCtD
Praziquantel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000222	0.00542	CcSEcCtD
Praziquantel—Discomfort—Epirubicin—bone cancer	0.000221	0.00539	CcSEcCtD
Praziquantel—Malaise—Doxorubicin—bone cancer	0.000219	0.00535	CcSEcCtD
Praziquantel—Vertigo—Doxorubicin—bone cancer	0.000219	0.00533	CcSEcCtD
Praziquantel—Anorexia—Methotrexate—bone cancer	0.000219	0.00533	CcSEcCtD
Praziquantel—CYP3A7—Biological oxidations—GSTP1—bone cancer	0.000218	0.00298	CbGpPWpGaD
Praziquantel—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	0.000215	0.00294	CbGpPWpGaD
Praziquantel—Convulsion—Doxorubicin—bone cancer	0.000211	0.00514	CcSEcCtD
Praziquantel—Nervous system disorder—Epirubicin—bone cancer	0.000211	0.00513	CcSEcCtD
Praziquantel—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000209	0.00286	CbGpPWpGaD
Praziquantel—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000209	0.00509	CcSEcCtD
Praziquantel—Skin disorder—Epirubicin—bone cancer	0.000209	0.00508	CcSEcCtD
Praziquantel—Myalgia—Doxorubicin—bone cancer	0.000207	0.00505	CcSEcCtD
Praziquantel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000206	0.00501	CcSEcCtD
Praziquantel—Discomfort—Doxorubicin—bone cancer	0.000205	0.00499	CcSEcCtD
Praziquantel—Anorexia—Epirubicin—bone cancer	0.000205	0.00498	CcSEcCtD
Praziquantel—Somnolence—Methotrexate—bone cancer	0.000204	0.00497	CcSEcCtD
Praziquantel—Decreased appetite—Methotrexate—bone cancer	0.000199	0.00486	CcSEcCtD
Praziquantel—Gastrointestinal disorder—Methotrexate—bone cancer	0.000198	0.00482	CcSEcCtD
Praziquantel—Fatigue—Methotrexate—bone cancer	0.000198	0.00482	CcSEcCtD
Praziquantel—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000196	0.00476	CcSEcCtD
Praziquantel—Nervous system disorder—Doxorubicin—bone cancer	0.000195	0.00474	CcSEcCtD
Praziquantel—Skin disorder—Doxorubicin—bone cancer	0.000193	0.0047	CcSEcCtD
Praziquantel—Somnolence—Epirubicin—bone cancer	0.000191	0.00465	CcSEcCtD
Praziquantel—Anorexia—Doxorubicin—bone cancer	0.000189	0.00461	CcSEcCtD
Praziquantel—Feeling abnormal—Methotrexate—bone cancer	0.000189	0.0046	CcSEcCtD
Praziquantel—Gastrointestinal pain—Methotrexate—bone cancer	0.000188	0.00457	CcSEcCtD
Praziquantel—Decreased appetite—Epirubicin—bone cancer	0.000187	0.00454	CcSEcCtD
Praziquantel—Gastrointestinal disorder—Epirubicin—bone cancer	0.000185	0.00451	CcSEcCtD
Praziquantel—Fatigue—Epirubicin—bone cancer	0.000185	0.00451	CcSEcCtD
Praziquantel—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.000184	0.00252	CbGpPWpGaD
Praziquantel—Urticaria—Methotrexate—bone cancer	0.000182	0.00444	CcSEcCtD
Praziquantel—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000182	0.00249	CbGpPWpGaD
Praziquantel—Abdominal pain—Methotrexate—bone cancer	0.000181	0.00442	CcSEcCtD
Praziquantel—Body temperature increased—Methotrexate—bone cancer	0.000181	0.00442	CcSEcCtD
Praziquantel—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000181	0.00441	CcSEcCtD
Praziquantel—Feeling abnormal—Epirubicin—bone cancer	0.000177	0.00431	CcSEcCtD
Praziquantel—Somnolence—Doxorubicin—bone cancer	0.000177	0.0043	CcSEcCtD
Praziquantel—Gastrointestinal pain—Epirubicin—bone cancer	0.000176	0.00428	CcSEcCtD
Praziquantel—Decreased appetite—Doxorubicin—bone cancer	0.000173	0.00421	CcSEcCtD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000172	0.00235	CbGpPWpGaD
Praziquantel—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000171	0.00418	CcSEcCtD
Praziquantel—Fatigue—Doxorubicin—bone cancer	0.000171	0.00417	CcSEcCtD
Praziquantel—Urticaria—Epirubicin—bone cancer	0.000171	0.00415	CcSEcCtD
Praziquantel—Body temperature increased—Epirubicin—bone cancer	0.00017	0.00413	CcSEcCtD
Praziquantel—Abdominal pain—Epirubicin—bone cancer	0.00017	0.00413	CcSEcCtD
Praziquantel—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.00017	0.00232	CbGpPWpGaD
Praziquantel—Hypersensitivity—Methotrexate—bone cancer	0.000169	0.00412	CcSEcCtD
Praziquantel—Asthenia—Methotrexate—bone cancer	0.000165	0.00401	CcSEcCtD
Praziquantel—Feeling abnormal—Doxorubicin—bone cancer	0.000164	0.00399	CcSEcCtD
Praziquantel—Gastrointestinal pain—Doxorubicin—bone cancer	0.000162	0.00396	CcSEcCtD
Praziquantel—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000162	0.00222	CbGpPWpGaD
Praziquantel—Pruritus—Methotrexate—bone cancer	0.000162	0.00395	CcSEcCtD
Praziquantel—Hypersensitivity—Epirubicin—bone cancer	0.000158	0.00385	CcSEcCtD
Praziquantel—Urticaria—Doxorubicin—bone cancer	0.000158	0.00384	CcSEcCtD
Praziquantel—CYP3A5—Biological oxidations—GSTP1—bone cancer	0.000158	0.00216	CbGpPWpGaD
Praziquantel—Abdominal pain—Doxorubicin—bone cancer	0.000157	0.00382	CcSEcCtD
Praziquantel—Body temperature increased—Doxorubicin—bone cancer	0.000157	0.00382	CcSEcCtD
Praziquantel—Diarrhoea—Methotrexate—bone cancer	0.000157	0.00382	CcSEcCtD
Praziquantel—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.000155	0.00213	CbGpPWpGaD
Praziquantel—Asthenia—Epirubicin—bone cancer	0.000154	0.00375	CcSEcCtD
Praziquantel—CYP3A7—Metabolism—NDUFA12—bone cancer	0.000153	0.00209	CbGpPWpGaD
Praziquantel—Pruritus—Epirubicin—bone cancer	0.000152	0.0037	CcSEcCtD
Praziquantel—Dizziness—Methotrexate—bone cancer	0.000152	0.00369	CcSEcCtD
Praziquantel—Diarrhoea—Epirubicin—bone cancer	0.000147	0.00358	CcSEcCtD
Praziquantel—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000147	0.002	CbGpPWpGaD
Praziquantel—Hypersensitivity—Doxorubicin—bone cancer	0.000146	0.00356	CcSEcCtD
Praziquantel—Vomiting—Methotrexate—bone cancer	0.000146	0.00355	CcSEcCtD
Praziquantel—Rash—Methotrexate—bone cancer	0.000145	0.00352	CcSEcCtD
Praziquantel—Dermatitis—Methotrexate—bone cancer	0.000144	0.00352	CcSEcCtD
Praziquantel—Headache—Methotrexate—bone cancer	0.000144	0.0035	CcSEcCtD
Praziquantel—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.000143	0.00195	CbGpPWpGaD
Praziquantel—Asthenia—Doxorubicin—bone cancer	0.000143	0.00347	CcSEcCtD
Praziquantel—Dizziness—Epirubicin—bone cancer	0.000142	0.00346	CcSEcCtD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000141	0.00193	CbGpPWpGaD
Praziquantel—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000141	0.00192	CbGpPWpGaD
Praziquantel—Pruritus—Doxorubicin—bone cancer	0.000141	0.00342	CcSEcCtD
Praziquantel—CYP3A43—Metabolism—ENO2—bone cancer	0.000138	0.00188	CbGpPWpGaD
Praziquantel—Vomiting—Epirubicin—bone cancer	0.000136	0.00332	CcSEcCtD
Praziquantel—Nausea—Methotrexate—bone cancer	0.000136	0.00332	CcSEcCtD
Praziquantel—Diarrhoea—Doxorubicin—bone cancer	0.000136	0.00331	CcSEcCtD
Praziquantel—Rash—Epirubicin—bone cancer	0.000135	0.0033	CcSEcCtD
Praziquantel—Dermatitis—Epirubicin—bone cancer	0.000135	0.00329	CcSEcCtD
Praziquantel—Headache—Epirubicin—bone cancer	0.000134	0.00328	CcSEcCtD
Praziquantel—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000132	0.00181	CbGpPWpGaD
Praziquantel—Dizziness—Doxorubicin—bone cancer	0.000131	0.0032	CcSEcCtD
Praziquantel—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000131	0.00179	CbGpPWpGaD
Praziquantel—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.000129	0.00177	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—DHFR—bone cancer	0.000128	0.00175	CbGpPWpGaD
Praziquantel—Nausea—Epirubicin—bone cancer	0.000128	0.00311	CcSEcCtD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000127	0.00174	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—NT5C3A—bone cancer	0.000127	0.00173	CbGpPWpGaD
Praziquantel—Vomiting—Doxorubicin—bone cancer	0.000126	0.00308	CcSEcCtD
Praziquantel—Rash—Doxorubicin—bone cancer	0.000125	0.00305	CcSEcCtD
Praziquantel—Dermatitis—Doxorubicin—bone cancer	0.000125	0.00305	CcSEcCtD
Praziquantel—Headache—Doxorubicin—bone cancer	0.000124	0.00303	CcSEcCtD
Praziquantel—CYP2C19—Biological oxidations—GSTP1—bone cancer	0.000122	0.00167	CbGpPWpGaD
Praziquantel—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	0.00012	0.00164	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—GNA11—bone cancer	0.000119	0.00163	CbGpPWpGaD
Praziquantel—Nausea—Doxorubicin—bone cancer	0.000118	0.00287	CcSEcCtD
Praziquantel—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.000113	0.00155	CbGpPWpGaD
Praziquantel—CYP2D6—Biological oxidations—GSTP1—bone cancer	0.000112	0.00153	CbGpPWpGaD
Praziquantel—CYP1A2—Biological oxidations—CYP3A4—bone cancer	0.000111	0.00152	CbGpPWpGaD
Praziquantel—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	0.000111	0.00151	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—NDUFA12—bone cancer	0.00011	0.00151	CbGpPWpGaD
Praziquantel—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	0.00011	0.0015	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—CYP3A4—bone cancer	0.000108	0.00148	CbGpPWpGaD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.0001	0.00137	CbGpPWpGaD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.0001	0.00137	CbGpPWpGaD
Praziquantel—CYP1A2—Biological oxidations—GSTP1—bone cancer	9.5e-05	0.0013	CbGpPWpGaD
Praziquantel—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	9.37e-05	0.00128	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—GSTP1—bone cancer	9.26e-05	0.00127	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—NT5C3A—bone cancer	9.16e-05	0.00125	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—NDUFA12—bone cancer	8.54e-05	0.00117	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—NDUFA12—bone cancer	7.86e-05	0.00107	CbGpPWpGaD
Praziquantel—CYP3A4—Biological oxidations—GSTP1—bone cancer	7.33e-05	0.001	CbGpPWpGaD
Praziquantel—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	7.23e-05	0.000988	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—NT5C3A—bone cancer	7.08e-05	0.000968	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—NDUFA12—bone cancer	6.66e-05	0.00091	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—NT5C3A—bone cancer	6.51e-05	0.00089	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—ENO2—bone cancer	5.55e-05	0.000758	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—NT5C3A—bone cancer	5.52e-05	0.000754	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—DHFR—bone cancer	5.15e-05	0.000704	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—NDUFA12—bone cancer	5.14e-05	0.000702	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—GNA11—bone cancer	4.81e-05	0.000658	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—PTGS2—bone cancer	4.8e-05	0.000656	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—CYP3A4—bone cancer	4.36e-05	0.000596	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—NT5C3A—bone cancer	4.26e-05	0.000582	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—ENO2—bone cancer	4.01e-05	0.000548	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—GSTP1—bone cancer	3.73e-05	0.00051	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—DHFR—bone cancer	3.72e-05	0.000509	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—GNA11—bone cancer	3.48e-05	0.000475	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—CYP3A4—bone cancer	3.15e-05	0.000431	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—ENO2—bone cancer	3.1e-05	0.000424	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—DHFR—bone cancer	2.88e-05	0.000393	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—ENO2—bone cancer	2.85e-05	0.00039	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—GSTP1—bone cancer	2.7e-05	0.000369	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—GNA11—bone cancer	2.69e-05	0.000367	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—DHFR—bone cancer	2.65e-05	0.000362	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—GNA11—bone cancer	2.47e-05	0.000338	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—CYP3A4—bone cancer	2.44e-05	0.000333	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.42e-05	0.000331	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—ENO2—bone cancer	2.42e-05	0.00033	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—CYP3A4—bone cancer	2.24e-05	0.000306	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—DHFR—bone cancer	2.24e-05	0.000306	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—GNA11—bone cancer	2.09e-05	0.000286	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—GSTP1—bone cancer	2.08e-05	0.000285	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—PTGS2—bone cancer	1.93e-05	0.000264	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—GSTP1—bone cancer	1.92e-05	0.000262	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—CYP3A4—bone cancer	1.9e-05	0.00026	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.89e-05	0.000258	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—ENO2—bone cancer	1.86e-05	0.000255	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—DHFR—bone cancer	1.73e-05	0.000236	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—GSTP1—bone cancer	1.62e-05	0.000222	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—GNA11—bone cancer	1.62e-05	0.000221	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—PTGS2—bone cancer	1.4e-05	0.000191	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—GSTP1—bone cancer	1.25e-05	0.000171	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—PTGS2—bone cancer	1.08e-05	0.000148	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—PTGS2—bone cancer	9.93e-06	0.000136	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—PTGS2—bone cancer	8.41e-06	0.000115	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—PTGS2—bone cancer	6.49e-06	8.88e-05	CbGpPWpGaD
